S&P 500   3,323.86 (+0.21%)
DOW   29,312.37 (+0.05%)
QQQ   222.77 (+0.22%)
AAPL   317.10 (+0.59%)
MSFT   166.41 (+0.14%)
GOOGL   1,471.23 (+1.45%)
AMZN   1,860.61 (-0.92%)
CGC   25.21 (+3.74%)
NVDA   248.51 (-0.17%)
BABA   226.10 (+0.96%)
GE   11.82 (-0.17%)
AMD   50.85 (+2.17%)
T   38.32 (+0.76%)
ACB   2.12 (-1.40%)
F   9.16 (-0.11%)
BAC   34.65 (-0.20%)
GILD   62.87 (-0.52%)
DIS   144.53 (-0.41%)
S&P 500   3,323.86 (+0.21%)
DOW   29,312.37 (+0.05%)
QQQ   222.77 (+0.22%)
AAPL   317.10 (+0.59%)
MSFT   166.41 (+0.14%)
GOOGL   1,471.23 (+1.45%)
AMZN   1,860.61 (-0.92%)
CGC   25.21 (+3.74%)
NVDA   248.51 (-0.17%)
BABA   226.10 (+0.96%)
GE   11.82 (-0.17%)
AMD   50.85 (+2.17%)
T   38.32 (+0.76%)
ACB   2.12 (-1.40%)
F   9.16 (-0.11%)
BAC   34.65 (-0.20%)
GILD   62.87 (-0.52%)
DIS   144.53 (-0.41%)
S&P 500   3,323.86 (+0.21%)
DOW   29,312.37 (+0.05%)
QQQ   222.77 (+0.22%)
AAPL   317.10 (+0.59%)
MSFT   166.41 (+0.14%)
GOOGL   1,471.23 (+1.45%)
AMZN   1,860.61 (-0.92%)
CGC   25.21 (+3.74%)
NVDA   248.51 (-0.17%)
BABA   226.10 (+0.96%)
GE   11.82 (-0.17%)
AMD   50.85 (+2.17%)
T   38.32 (+0.76%)
ACB   2.12 (-1.40%)
F   9.16 (-0.11%)
BAC   34.65 (-0.20%)
GILD   62.87 (-0.52%)
DIS   144.53 (-0.41%)
S&P 500   3,323.86 (+0.21%)
DOW   29,312.37 (+0.05%)
QQQ   222.77 (+0.22%)
AAPL   317.10 (+0.59%)
MSFT   166.41 (+0.14%)
GOOGL   1,471.23 (+1.45%)
AMZN   1,860.61 (-0.92%)
CGC   25.21 (+3.74%)
NVDA   248.51 (-0.17%)
BABA   226.10 (+0.96%)
GE   11.82 (-0.17%)
AMD   50.85 (+2.17%)
T   38.32 (+0.76%)
ACB   2.12 (-1.40%)
F   9.16 (-0.11%)
BAC   34.65 (-0.20%)
GILD   62.87 (-0.52%)
DIS   144.53 (-0.41%)
Log in

NASDAQ:OMER - Omeros Stock Price, Forecast & News

$13.98
-0.82 (-5.54 %)
(As of 01/17/2020 03:06 PM ET)
Today's Range
$13.94
Now: $13.98
$14.88
50-Day Range
$13.07
MA: $13.98
$15.30
52-Week Range
$12.52
Now: $13.98
$20.92
Volume15,687 shs
Average Volume527,959 shs
Market Capitalization$695.48 million
P/E RatioN/A
Dividend YieldN/A
Beta2.63
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:OMER
CUSIP68214310
Phone206-676-5000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.87 million
Book Value($2.04) per share

Profitability

Net Income$-126,760,000.00

Miscellaneous

Employees236
Market Cap$695.48 million
Next Earnings Date3/6/2020 (Estimated)
OptionableOptionable

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.


Omeros (NASDAQ:OMER) Frequently Asked Questions

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) posted its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.08. The biopharmaceutical company had revenue of $29.86 million for the quarter, compared to analysts' expectations of $27.19 million. The company's quarterly revenue was up 547.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.81) EPS. View Omeros' Earnings History.

When is Omeros' next earnings date?

Omeros is scheduled to release their next quarterly earnings announcement on Friday, March 6th 2020. View Earnings Estimates for Omeros.

What price target have analysts set for OMER?

5 equities research analysts have issued twelve-month price objectives for Omeros' stock. Their forecasts range from $18.00 to $34.00. On average, they expect Omeros' stock price to reach $25.75 in the next twelve months. This suggests a possible upside of 83.8% from the stock's current price. View Analyst Price Targets for Omeros.

What is the consensus analysts' recommendation for Omeros?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omeros.

Has Omeros been receiving favorable news coverage?

News headlines about OMER stock have trended positive recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Omeros earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Omeros.

Who are some of Omeros' key competitors?

What other stocks do shareholders of Omeros own?

Who are Omeros' key executives?

Omeros' management team includes the folowing people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 60)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 61)
  • Ms. Marcia S. Kelbon, VP of Patent, Gen. Counsel & Sec. (Age 59)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 56)
  • Dr. George A. Gaitanaris, Chief Scientific Officer & VP of Science (Age 62)

Who are Omeros' major shareholders?

Omeros' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Ingalls & Snyder LLC (9.35%), Cypress Capital Group (0.06%), Mesirow Financial Investment Management Inc. (0.05%) and Alpine Global Management LLC (0.04%). Company insiders that own Omeros stock include Marcia S Kelbon, Michael A Jacobsen and Thomas J Cable. View Institutional Ownership Trends for Omeros.

Which major investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including Ingalls & Snyder LLC and Mesirow Financial Investment Management Inc.. View Insider Buying and Selling for Omeros.

Which major investors are buying Omeros stock?

OMER stock was bought by a variety of institutional investors in the last quarter, including Alpine Global Management LLC and Cypress Capital Group. View Insider Buying and Selling for Omeros.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $14.01.

How big of a company is Omeros?

Omeros has a market capitalization of $696.97 million and generates $29.87 million in revenue each year. The biopharmaceutical company earns $-126,760,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Omeros employs 236 workers across the globe.View Additional Information About Omeros.

What is Omeros' official website?

The official website for Omeros is http://www.omeros.com/.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.


MarketBeat Community Rating for Omeros (NASDAQ OMER)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  686 (Vote Outperform)
Underperform Votes:  452 (Vote Underperform)
Total Votes:  1,138
MarketBeat's community ratings are surveys of what our community members think about Omeros and other stocks. Vote "Outperform" if you believe OMER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMER will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel